LUNSUMIO was evaluated in 90 patients with 3L+ FL
This study was a phase 2 clinical trial. This is a phase of a clinical trial that studies an investigational treatment to test how well it works and monitors for potential side effects. The effectiveness of LUNSUMIO was evaluated in 90 patients and the safety was evaluated in 218 patients.
Patients were monitored in order to determine whether LUNSUMIO produced overall response. This is a response to treatment that means patients either achieved complete remission (disappearance of all signs and symptoms of FL) or partial remission (some measurable decrease in presence of lymphoma).
*Including an anti-CD20 monoclonal antibody and an alkylating agent.
†Treatments included alkylating agents and anti-CD20 therapies (100%), autologous stem cell transplant (21%), PI3K inhibitors (19%), rituximab + lenalidomide therapy (9%), and CAR-T therapies (3%).
No matter what type of health insurance you have, and even if you have none at all, there may be financial assistance options available. Take a look at the details and benefits of the available programs below.
Learn more about available financial support
Explore questions you may want to ask your doctor.
Enroll in our patient support program to receive helpful information about treatment.
LUNSUMIO (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer.
It is not known if LUNSUMIO is safe and effective in children.
The conditional approval of LUNSUMIO is based on response rate. There are ongoing studies to establish how well the drug works.
LUNSUMIO may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with LUNSUMIO and can also be severe or life-threatening.
Get medical help right away if you develop any signs or symptoms of CRS at any time, including:
Due to the risk of CRS, you will receive LUNSUMIO on a “step-up dosing schedule.”
Your healthcare provider will check you for CRS during treatment with LUNSUMIO and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with LUNSUMIO, if you have severe side effects.
LUNSUMIO may cause serious side effects, including:
Your healthcare provider may temporarily stop or permanently stop treatment with LUNSUMIO if you develop severe side effects.
The most common side effects of LUNSUMIO include: tiredness, rash, fever, and headache.
The most common severe abnormal lab test results with LUNSUMIO include: decreased phosphate, increased glucose, and increased uric acid levels.
Before receiving LUNSUMIO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.
These are not all the possible side effects of LUNSUMIO. Talk to your health care provider for more information about the benefits and risks of LUNSUMIO.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the LUNSUMIO full Prescribing Information and Medication Guide.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.